title: Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.
authors.affiliation: Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. david_hunt200@hotmail.com.
authors.forename: N C
authors.initials: NC
authors.lastname: Hare
authors.forename: D P J
authors.initials: DP
authors.lastname: Hunt
authors.forename: K
authors.initials: K
authors.lastname: Venugopal
authors.forename: G-T
authors.initials: GT
authors.lastname: Ho
authors.forename: T
authors.initials: T
authors.lastname: Beez
authors.forename: C W
authors.initials: CW
authors.lastname: Lees
authors.forename: R
authors.initials: R
authors.lastname: Gibson
authors.forename: B
authors.initials: B
authors.lastname: Weller
authors.forename: J
authors.initials: J
authors.lastname: Satsangi
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D003937:Diagnosis, Differential; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab